United States· US:36000-300_f87dcd07-90ef-4e37-853e-7a5911a038b1
dihydroergotamine mesylate
A dihydroergotamine product containing dihydroergotamine mesylate, registered in United States by Baxter Healthcare Corporation. The same ATC class is registered in 8 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Dihydroergotamine is registered in 8 of 19 countries.
Countries holding a registration under ATC N02CA01 (dihydroergotamine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 6 of them publish a price we can compare per daily dose
Dihydroergotamine · ATC N02CA01
8 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Franceprice
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DIHYDROERGOTAMINE MESYLATE
- Manufacturer
- Baxter Healthcare Corporation
- Country
- United States (US)
- ATC code
- N02CA01
- ATC class
- Dihydroergotamine
- Defined daily dose
- 1 mg, N
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1136000-300-10
- ndc11360003001010 AMPULE in 1 CARTON (36000-300-10) / 1 mL in 1 AMPULE (36000-300-01)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
178 interactions on record for dihydroergotamine.
Graded by severity as the source publishes them — 54 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dihydroergotamine · interactions on record
178 records
- 54 severe
- 90 moderate
- 1 minor
- 17 info
Most severe, free to view
- EpinephrineA01AD01severe
- IsomethepteneA03AX10severe
- FenfluramineA08AA02severe
- DexfenfluramineA08AA04severe
16 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dihydroergotamine in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumDiergo Spray 4 mg/mlAmdipharm
- SwedenOrstanorm 2,5 mg TablettAmdipharm Limited
- CanadaDIHYDROERGOTAMINE (DHE), 1MG/MLSTERIMAX INC
- United KingdomDihydroergotamine 1mg/1ml solution for injection ampoulesImported (Canada)
- FinlandMigranalNovartis Finland Oy
- PolandDihydroergotaminum FilofarmFarmaceutyczna Spółdzielnia Pracy FILOFARM
- NorwayDihydroergotamine sterimax
- FranceDIERGOSPRAY 4 mg/ml, solution pour pulvérisation nasaleAMDIPHARM
Authorised across Europe · EMA
The same active substance is authorised in 8 EEA countries. Names it is sold under:
- Austria · Dihydergot, Migranal
- Belgium · Diergo Spray
- France · Diergospray
- United Kingdom (Northern Ireland) · Migranal
- Greece · Dihydergot
- Italy · Diidergot, Dineza
- Poland · Dihydroergotaminum Filofarm
- Sweden · Orstanorm
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fd41c3d2-65be-495a-ad80-2b0dde50268c GET /v1/drugs/fd41c3d2-65be-495a-ad80-2b0dde50268c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS",
"source": "ndc",
"strength": "1",
"substance": "DIHYDROERGOTAMINE MESYLATE",
"productndc": "36000-300",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "ANDA216747",
"marketing_category": "ANDA"
}See everything about dihydroergotamine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.